A UCLA group and spinout FetoLumina Technologies are working on a clinical assay for noninvasive prenatal diagnostics.
At a conference last week, researchers from Italy presented results from 73 women who had mosaic embryos transferred.
Premaitha will issue Thermo Fisher warrants over 28,938,797 new ordinary shares and a second tranche of warrants in 2018.
Counsyl believes its data is robust, while Natera has called the methodology and conclusions "gratuitously wrong." Both published opposing response letters this week.
According to John Zhang, founder and CEO of the New Hope Fertility Center, universal PGS will likely increase success rates of IVF further.
A study by researchers in Italy found that preimplantation genetic diagnosis and screening combined led to more successful pregnancies per transfer but fewer women had embryos transferred.
At last week's ESHG annual meeting, three quality assessment providers discussed best practice guidelines and results from a pilot NIPT quality assessment scheme.
In a report made public this week, the French National Authority for Health recommended NIPT if first semester screening indicated a risk between 1 in 51 and 1 in 1,000.
For the year ended March 31, the Manchester, UK-based provider of noninvasive prenatal testing reported more than £3.1 million ($4 million) in revenue.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.